

# Nesrine Gamal

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8069857/nesrine-gamal-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

14  
papers

125  
citations

4  
h-index

11  
g-index

16  
ext. papers

147  
ext. citations

2.8  
avg, IF

2.41  
L-index

#	Paper	IF	Citations
14	Subjects with blood group O are not at lower risk to acquire SARS-CoV-2 infection. <i>Vox Sanguinis</i> , <b>2021</b> , 116, 471-472	3.1	2
13	Quality of life of hepatitis B virus surface antigen-positive patients with suppressed viral replication: comparison between inactive carriers and nucleot(s)ide analog-treated patients. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2018</b> , 30, 14-20	2.2	3
12	Differences in liver stiffness values obtained with new ultrasound elastography machines and Fibroscan: A comparative study. <i>Digestive and Liver Disease</i> , <b>2017</b> , 49, 802-808	3.3	41
11	NS5A inhibitors for the treatment of hepatitis C infection. <i>Journal of Viral Hepatitis</i> , <b>2017</b> , 24, 180-186	3.4	20
10	Safety and efficacy of once daily ledipasvir/sofosbuvir fixed-dose combination in patients with chronic hepatitis C. <i>Expert Opinion on Drug Safety</i> , <b>2016</b> , 15, 549-57	4.1	2
9	Efficacy and Safety of Daclatasvir in Hepatitis C: An Overview. <i>Journal of Clinical and Translational Hepatology</i> , <b>2016</b> , 4, 336-344	5.2	4
8	⌈Bile salt export pump deficiency disease: two novel, late onset, ABCB11 mutations identified by next generation sequencing. <i>Annals of Hepatology</i> , <b>2016</b> , 15, 795-800	3.1	4
7	Paritaprevir in patients with chronic hepatitis C genotype 1. <i>Future Virology</i> , <b>2015</b> , 10, 679-690	2.4	1
6	Prospective, observational real-life study on eligibility for and outcomes of antiviral treatment with peginterferon ⌈plus ribavirin in chronic hepatitis C. <i>Digestive and Liver Disease</i> , <b>2015</b> , 47, 151-6	3.3	4
5	ABT-450: a novel agent for the treatment of CHC genotype 1: focus on treatment-experienced patients. <i>Expert Review of Anti-Infective Therapy</i> , <b>2015</b> , 13, 295-304	5.5	4
4	Working together to tackle HCV infection: ombitasvir/paritaprevir/ritonavir and dasabuvir combination. <i>Drugs of Today</i> , <b>2015</b> , 51, 303-14	2.5	4
3	Adaptive response in hepatitis B virus infection. <i>Journal of Viral Hepatitis</i> , <b>2014</b> , 21, 305-13	3.4	31
2	Alopecia universalis after discontinuation of pegylated interferon and ribavirin combination therapy for hepatitis C: a case report. <i>Annals of Hepatology</i> , <b>2014</b> , 13, 293-296	3.1	3
1	Alopecia universalis after discontinuation of pegylated interferon and ribavirin combination therapy for hepatitis C: a case report. <i>Annals of Hepatology</i> , <b>2014</b> , 13, 293-6	3.1	1